Diplomat Pharmacy, Inc. (NYSE:DPLO) issued an update on its FY17 earnings guidance on Monday morning. The company provided earnings per share guidance of $0.71-0.79 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $0.65. The company issued revenue guidance of $4.3-4.6 billion, compared to the consensus revenue estimate of $4.57 billion.

Diplomat Pharmacy, Inc. (NYSE DPLO) traded up 2.97% during mid-day trading on Monday, reaching $15.26. 864,178 shares of the company’s stock traded hands. The stock has a 50-day moving average price of $16.05 and a 200-day moving average price of $15.66. Diplomat Pharmacy, Inc. has a 12-month low of $12.25 and a 12-month high of $38.94. The stock has a market capitalization of $1.02 billion, a PE ratio of 60.80 and a beta of 0.66.

Diplomat Pharmacy (NYSE:DPLO) last issued its quarterly earnings data on Monday, May 8th. The company reported $0.19 EPS for the quarter, topping analysts’ consensus estimates of $0.15 by $0.04. Diplomat Pharmacy had a net margin of 0.38% and a return on equity of 7.91%. The business had revenue of $1.08 billion during the quarter, compared to analysts’ expectations of $1.08 billion. During the same period last year, the company posted $0.23 EPS. The business’s revenue was up 8.3% on a year-over-year basis. Equities research analysts expect that Diplomat Pharmacy, Inc. will post $0.65 EPS for the current year.

DPLO has been the subject of a number of recent research reports. Mizuho lifted their price objective on shares of Diplomat Pharmacy from $17.00 to $19.00 and gave the stock a neutral rating in a research note on Tuesday, May 16th. Zacks Investment Research cut shares of Diplomat Pharmacy from a hold rating to a sell rating in a research note on Monday, July 17th. BidaskClub cut shares of Diplomat Pharmacy from a buy rating to a hold rating in a research note on Thursday, June 29th. Bank of America Corporation lifted their price objective on shares of Diplomat Pharmacy from $17.00 to $18.50 and gave the stock a neutral rating in a research note on Thursday, May 25th. Finally, Needham & Company LLC initiated coverage on shares of Diplomat Pharmacy in a research note on Friday, July 21st. They issued a buy rating and a $19.75 price objective for the company. Four equities research analysts have rated the stock with a sell rating, eight have issued a hold rating and two have issued a buy rating to the company. The company currently has a consensus rating of Hold and an average target price of $20.91.

TRADEMARK VIOLATION WARNING: This news story was first posted by American Banking News and is the property of of American Banking News. If you are viewing this news story on another site, it was copied illegally and reposted in violation of international copyright & trademark law. The correct version of this news story can be read at https://www.americanbankingnews.com/2017/08/07/diplomat-pharmacy-inc-nysedplo-updates-fy17-earnings-guidance.html.

Diplomat Pharmacy Company Profile

Diplomat Pharmacy, Inc (Diplomat) operates a specialty pharmacy business, which stocks, dispenses and distributes prescriptions for various biotechnology and specialty pharmaceutical manufacturers. The Company operates through specialty pharmacy services segment. The Company’s primary focus is on medication management programs for individuals with chronic diseases, including oncology, immunology, hepatitis, multiple sclerosis, specialty infusion therapy, and various other serious and/or long-term conditions.

Receive News & Ratings for Diplomat Pharmacy Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Diplomat Pharmacy Inc. and related companies with MarketBeat.com's FREE daily email newsletter.